Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
07 09 2021
Historique:
received: 08 03 2021
revised: 04 08 2021
accepted: 07 08 2021
pubmed: 17 8 2021
medline: 3 9 2021
entrez: 16 8 2021
Statut: ppublish

Résumé

Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020. This is a retrospective analysis of serological data, showing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli health care workers receiving BNT162b2. Sero-conversion occurred in 14 days in all study participants, with IgG levels peaking approximately 30 days after initiation of the vaccination series. A statistically significant difference was observed in IgG levels between subjects younger than 50 years and older participants, although in all cases, IgG levels were well above the level considered reactive by the test's manufacturer. The importance of this difference needs to be studied further, but a potential difference in vaccine efficacy and vaccine effect length could possibly be present between these two groups.

Identifiants

pubmed: 34393018
pii: S0264-410X(21)01045-8
doi: 10.1016/j.vaccine.2021.08.025
pmc: PMC8354802
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Immunoglobulin G 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5337-5340

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

JAMA Netw Open. 2021 Mar 1;4(3):e214302
pubmed: 33749770
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
BMC Med. 2021 Jul 26;19(1):169
pubmed: 34304742
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591
pubmed: 33838087
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Infect Public Health. 2021 Aug;14(8):1120-1122
pubmed: 34293641

Auteurs

Daniel Grupel (D)

Ben-Gurion University, Beer Sheva, Israel. Electronic address: daniel@grupel.com.

Sivan Gazit (S)

Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Israel.

Licita Schreiber (L)

Maccabi Healthcare Services, Central Laboratory, Rehovot, Israel.

Varda Nadler (V)

Maccabi Healthcare Services, Central Laboratory, Rehovot, Israel.

Tamar Wolf (T)

Maccabi Healthcare Services, Central Laboratory, Rehovot, Israel.

Rachel Lazar (R)

Maccabi Healthcare Services, Central Laboratory, Rehovot, Israel.

Lia Supino-Rosin (L)

Maccabi Healthcare Services, Central Laboratory, Rehovot, Israel.

Galit Perez (G)

Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Israel.

Asaf Peretz (A)

Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital, Ashdod, Israel.

Amir Ben Tov (A)

Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Miri Mizrahi-Reuveni (M)

Health Division, Maccabi Healthcare Services, Tel Aviv, Israel.

Gabriel Chodick (G)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.

Tal Patalon (T)

Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH